Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Female Genital Erosive Lichen Planus
NCT03656666Phase 2Unknown
- Sponsor
- Oslo University Hospital
- Start
- Sep 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in erosive lichen planus (ELP) comparing Apremilast with Placebo (2 arms). Primary endpoint: Genital Erosive Lichen Planus Score at 24 weeks. Status: unknown.
02
Drugs
apremilast
03
Conditions
erosive lichen planus (ELP)
Beyond the preview
Go deeper on NCT03656666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656666.